[Summary] Dedicated to the research and development of tumor immunotherapy cell
About Fosun Kite
Founded in 2017, Fosun Kite (Shanghai) Biotechnology Co., Ltd. has long been committed to the research and development of tumor immunotherapy cell therapy. In June 2021, it took the lead in obtaining approval to launch China's first CAR-T cell therapy product, Yikaida®, successfully treating over 500 patients with relapsed/refractory large B-cell lymphoma.
In December 2019, the company officially launched its nearly 10,000 m² CAR-T industrialization production base located in Zhangjiang, Shanghai, and established a cell therapy R&D center of over 2,000 m², successfully bringing together and cultivating an innovative talent team of highly educated, high-quality R&D scientists from home and abroad.
On June 21, 2023, the new indication application for Yikaida® submitted by Fosun Kite was officially approved by the National Medical Products Administration. This also marks that adult patients with large B-cell lymphoma who are refractory to first-line immunochemotherapy or relapse within 12 months after first-line immunochemotherapy will benefit faster and usher in hope for a cure.
What does Fosun Kite (Shanghai) Biotechnology Co., Ltd. require? Who is Fosun Kite hiring? Fosun Kite recruitment: 其他类占比最多占40.2%，其次是生物/制药/化工/环保类占14.3%. What education can get in at Fosun Kite? 大专占比最多占57.1%，其次是本科占30.4%. High education required at Fosun Kite? 硕士占10.7%. Work experience required at Fosun Kite? 3-5年占比最多占40.2%，其次是不限占36.6%. Where are the job locations at Fosun Kite? 上海占比最多占29.5%，其次是深圳占21.4%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
